These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 16262971

  • 1. Ximelagatran: a new type of oral anticoagulant.
    Kwok L, Molckovsky D, Boucher M.
    Int J Technol Assess Health Care; 2005; 21(4):480-6. PubMed ID: 16262971
    [Abstract] [Full Text] [Related]

  • 2. Ximelagatran in prevention of cardiovascular events.
    Molckovsky D, Boucher M.
    Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
    [Abstract] [Full Text] [Related]

  • 3. Ximelagatran: a new oral anticoagulant.
    Hrebickova L, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Nov; 5(6):397-408. PubMed ID: 14633322
    [Abstract] [Full Text] [Related]

  • 4. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R, Tran M, Gore JM, Spencer FA.
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [Abstract] [Full Text] [Related]

  • 5. Ximelagatran for prevention and treatment of venous thromboembolism.
    Kwok L, Boucher M.
    Issues Emerg Health Technol; 2004 Jun; (57):1-4. PubMed ID: 15214359
    [Abstract] [Full Text] [Related]

  • 6. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran.
    Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B, EXTEND Study Group.
    Thromb Res; 2009 Jun; 123(3):488-97. PubMed ID: 18485453
    [Abstract] [Full Text] [Related]

  • 7. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 8. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 9. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H, Selçuk MT, Maden O.
    Anadolu Kardiyol Derg; 2007 Mar 30; 7(1):54-8. PubMed ID: 17347079
    [Abstract] [Full Text] [Related]

  • 10. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL.
    J Am Coll Cardiol; 2005 Jan 04; 45(1):1-9. PubMed ID: 15629364
    [Abstract] [Full Text] [Related]

  • 11. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ.
    Rev Cardiovasc Med; 2004 Jan 04; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [Abstract] [Full Text] [Related]

  • 12. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA, Dorrell KA, Sandberg KR, Yerkey MW.
    Rev Cardiovasc Med; 2004 Jan 04; 5(2):99-103. PubMed ID: 15184843
    [Abstract] [Full Text] [Related]

  • 13. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ, Frison L, Weaver D, Wilcox RG, Bylock A, Emanuelsson H, Held P, Oldgren J.
    Am Heart J; 2008 Feb 04; 155(2):382-7. PubMed ID: 18215612
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov 04; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios.
    Reiffel JA.
    Rev Cardiovasc Med; 2004 Nov 04; 5 Suppl 5():S12-21. PubMed ID: 15619610
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.